Therapeutic potential of IL-27 in multiple sclerosis?

Expert Opinion on Biological Therapy

Volumn 9, Issue 2, 2009, Pages 149-160

  Fitzgerald, Denise C ^b   Rostami, Abdolmohamad ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

Experimental autoimmune encephalomyelitis (EAE); IL 27; Inflammation; Multiple sclerosis (MS); Th1; Th17

Indexed keywords

AMINO ACID; BETA INTERFERON; GLATIRAMIER ACETATE; INTERLEUKIN 10; INTERLEUKIN 27; MITOXANTRONE; NATALIZUMAB; PROTEOLIPID PROTEIN; UNCLASSIFIED DRUG; INTERLEUKIN 17;

AUTOIMMUNE DISEASE; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG ACTIVITY; ENCEPHALOMYELITIS; HELPER CELL; HUMAN; IMMUNIZATION; IMMUNOMODULATION; IMMUNOPATHOLOGY; INFECTION; INFLAMMATION; MULTIPLE SCLEROSIS; NONHUMAN; PATHOGENESIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; T LYMPHOCYTE; UPREGULATION; ANIMAL; IMMUNOLOGY;

ANIMALS; AUTOIMMUNE DISEASES; HUMANS; INTERLEUKIN-17; MULTIPLE SCLEROSIS; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 66149095150     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590802646936     Document Type: Review

References (126)

1. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005;23:683-747 (Pubitemid 40563183)
2. Alonso A. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology 2008;71:129-135
3. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112 (Pt 1):133-146
4. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907-911 (Pubitemid 26134623)
5. Bjartmar C, Trapp BD. Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr Opin Neurol 2001;14:271-278 (Pubitemid 32510589)
6. Bjartmar C, Wujek JR, Trapp BD. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J Neurol Sci 2003;206:165-171 (Pubitemid 36143722)
7. Prineas JW, Kwon EE, Cho ES, Sharer LR. Continual breakdown and regeneration of myelin in progressive multiple sclerosis plaques. Ann NY Acad Sci 1984;436:11-32 (Pubitemid 15102029)
8. Prineas JW, Kwon EE, Cho ES, Sharer LR. Multiple sclerosis. Pathology of recurrent lesions. Brain 1993;116 ( Pt 3):681-693
9. Chang A, Smith MC, Yin X, et al. Neurogenesis in the chronic lesions of multiple sclerosis. Brain 2008;131:2366-2375
10. Lamoureux G, Borduas AG. Immune studies in multiple sclerosis. Clin Exp Immunol 1966;1:363-376
11. Lisak RP, Levinson AI, Zweiman B, Abdou NI. T and B lymphocytes in multiple sclerosis. Clin Exp Immunol 1975;22:30-34
12. Bar-or A. The immunology of multiple sclerosis. Semin Neurol 2008;28:29-45 (Pubitemid 351273082)
13. Bansil S, Cook SD, Rohowsky-Kochan C. Multiple sclerosis: immune mechanism and update on current therapies. Ann Neurol 1995;37 (Suppl 1):S87-101
14. Agrawal SM, Yong VW. Immunopathogenesis of multiple sclerosis. Int Rev Neurobiol 2007;79:99-126
15. Connelly JF. Interferon beta for multiple sclerosis. Ann Pharmacother 1994;28:610-616 (Pubitemid 24141469)
16. Manfredonia F, Pasquali L, Dardano A, et al. Review of the clinical evidence for interferon β1a (Rebif®) in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat 2008;4:321-336 (Pubitemid 351711928)
17. Goodin DS, Frohman EM, Garmany GP, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002;58:169-178 (Pubitemid 34086933)
18. Clerico M, Contessa G, Durelli L. Interferon-β1a for the treatment of multiple sclerosis. Expert Opin Biol Ther 2007;7:535-542 (Pubitemid 46524677)
19. Yong VW, Chabot S, Stuve O, Williams G. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology 1998;51:682-689 (Pubitemid 28449243)
20. Markowitz CE. Interferon-beta: mechanism of action and dosing issues. Neurology 2007;68:S8-11
21. Blanchette F, Neuhaus O. Glatiramer acetate: evidence for a dual mechanism of action. J Neurol 2008;255 (Suppl 1):26-36 (Pubitemid 351341870)
22. Polman CH, O'connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910
23. Khalili K, White MK, Lublin F, et al. Reactivation of JC virus and development of PML in patients with multiple sclerosis. Neurology 2007;68:985-990 (Pubitemid 46569130)
24. Fox EJ. Mechanism of action of mitoxantrone. Neurology 2004;63:S15-18 (Pubitemid 40019273)
25. Steinman L, Zamvil SS. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann Neurol 2006;60:12-21
26. Drescher KM, Sosnowska D. Being a mouse in a man's world: what TMEV has taught us about human disease. Front Biosci 2008;13:3775-3785 (Pubitemid 351594658)
27. Matsushima GK, Morell P. The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system. Brain Pathol 2001;11:107-116
28. Mokhtarian F, Shi Y, Zhu PF, Grob D. Immune responses, and autoimmune outcome, during virus infection of the central nervous system. Cell Immunol 1994;157:195-210 (Pubitemid 24259464)
29. Matthews AE, Weiss SR, Paterson Y. Murine hepatitis virus-a model for virus-induced CNS demyelination. J Neurovirol 2002;8:76-85 (Pubitemid 34520889)
30. Ercolini AM, Miller SD. Mechanisms of immunopathology in murine models of central nervous system demyelinating disease. J Immunol 2006;176:3293-3298 (Pubitemid 43363973)
31. Mosmann TR, Cherwinski H, Bond MW, et al. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986;136:2348-2357
32. Szabo SJ, Sullivan BM, Peng SL, Glimcher LH. Molecular mechanisms regulating Th1 immune responses. Annu Rev Immunol 2003;21:713-758 (Pubitemid 37174546)
33. Constant SL, Bottomly K. Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Annu Rev Immunol 1997;15:297-322 (Pubitemid 27169283)
34. Ansel KM, Djuretic I, Tanasa B, Rao A. Regulation of Th2 differentiation and Il4 locus accessibility. Annu Rev Immunol 2006;24:607-656
35. Liew FY. TH1 and TH2 cells: a historical perspective. Nat Rev Immunol 2002;2:55-60
36. Moser M, Murphy KM. Dendritic cell regulation of TH1-TH2 development. Nat Immunol 2000;1:199-205
37. Infante-Duarte C, Kamradt T. Th1/Th2 balance in infection. Springer Semin Immunopathol 1999;21:317-338 (Pubitemid 30011442)
38. Singh VK, Mehrotra S, Agarwal SS. The paradigm of Th1 and Th2 cytokines: its relevance to autoimmunity and allergy. Immunol Res 1999;20:147-161
39. Ando DG, Clayton J, Kono D, et al. Encephalitogenic T cells in the B10.PL model of experimental allergic encephalomyelitis (EAE) are of the Th-1 lymphokine subtype. Cell Immunol 1989;124:132-143 (Pubitemid 20000271)
40. Merrill JE, Kono DH, Clayton J, et al. Inflammatory leukocytes and cytokines in the peptide-induced disease of experimental allergic encephalomyelitis in SJL and B10. PL mice. Proc Natl Acad Sci USA 1992;89:574-578
41. Gallo P, Piccinno MG, Tavolato B, Siden A. A longitudinal study on IL-2, sIL-2R, IL-4 and IFN-γ in multiple sclerosis CSF and serum. J Neurol Sci 1991;101:227-232
42. Voskuhl RR, Martin R, Bergman C, et al. T helper 1 (Th1) functional phenotype of human myelin basic protein-specific T lymphocytes. Autoimmunity 1993;15:137-143 (Pubitemid 23276008)
43. Ferber IA, Brocke S, Taylor-edwards C, et al. Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J Immunol 1996;156:5-7 (Pubitemid 3024744)
44. Krakowski M, Owens T. Interferon-γ confers resistance to experimental allergic encephalomyelitis. Eur J Immunol 1996;26:1641-1646
45. Voorthuis JA, Uitdehaag BM, De Groot CJ, et al. Suppression of experimental allergic encephalomyelitis by intraventricular administration of interferon-gamma in Lewis rats. Clin Exp Immunol 1990;81:183-188 (Pubitemid 20242519)
46. Willenborg DO, Fordham S, Bernard CC, et al. IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. J Immunol 1996;157:3223-3227 (Pubitemid 126449130)
47. Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005;6:1123-1132 (Pubitemid 41541790)
48. Park H, Li Z, Yang XO, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005;6:1133-1141 (Pubitemid 41541791)
49. Wynn TA. TH-17: a giant step from TH1 and TH2. Nat Immunol 2005;6:1069-1070
50. + T helper cells. Cell 2006;126:1121-1133
51. Yang XO, Pappu BP, Nurieva R, et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors RORα and RORγ. Immunity 2008;28:29-39
52. Yang L, Anderson DE, Baecher-allan C, et al. IL-21 and TGF-β are required for differentiation of human TH17 cells. Nature 2008;454:350-352
53. Manel N, Unutmaz D, Littman DR. The differentiation of human TH-17 cells requires transforming growth factor-β and induction of the nuclear receptor RORγt. Nat Immunol 2008;9:641-649 (Pubitemid 351714729)
54. Volpe E, Servant N, Zollinger R, et al. A critical function for transforming growth factor-β, interleukin 23 and proinflammatory cytokines in driving and modulating human TH-17 responses. Nat Immunol 2008;9:650-657 (Pubitemid 351712635)
55. O'Garra A, Stockinger B, Veldhoen M.Differentiation of human TH-17 cells does require TGF-β. Nat Immunol 2008;9:588-590 (Pubitemid 351712629)
56. Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007;8:950-957 (Pubitemid 47300009)
57. Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 2008;28:454-467
58. Korn T, Oukka M, Kuchroo V, Bettelli E. Th17 cells: effector T cells with inflammatory properties. Semin Immunol 2007;19:362-371 (Pubitemid 351274046)
59. Aujla SJ, Dubin PJ, Kolls JK. Th17 cells and mucosal host defense. Semin Immunol 2007;19:377-382 (Pubitemid 351274047)
60. Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005;201:233-240 (Pubitemid 40189432)
61. Mcgeachy MJ, Bak-jensen KS, Chen Y, et al. TGF-β and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain TH-17 cell-mediated pathology. Nat Immunol 2007;8:1390-1397 (Pubitemid 350138974)
62. Kebir H, Kreymborg K, Ifergan I, et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med 2007;13:1173-1175 (Pubitemid 47530640)
63. Tzartos JS, Friese MA, Craner MJ, et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 2008;172:146-155 (Pubitemid 351186376)
64. Stromnes IM, Cerretti LM, Liggitt D, et al. Differential regulation of central nervous system autoimmunity by TH1 and TH17 cells. Nat Med 2008;14:337-342
65. Kroenke MA, Carlson TJ, Andjelkovic AV, Segal BM. IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition. J Exp Med 2008;205:1535-1541 (Pubitemid 351962016)
66. O'connor RA, Prendergast CT, Sabatos CA, et al. Cutting Edge: Th1 cells facilitate the entry of Th17 cells to the central nervous system during experimental autoimmune encephalomyelitis. J Immunol 2008;181:3750-3754
67. Pflanz S, Timans JC, Cheung J, et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells. Immunity 2002;16:779-790 (Pubitemid 34786477)
68. Collison LW, Workman CJ, Kuo TT, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007;450:566-569 (Pubitemid 350190247)
69. Niedbala W, Wei XQ, Cai B, et al. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol 2007;37:3021-3029 (Pubitemid 350131282)
70. Fitzgerald DC, Ciric B, Touil T, et al. Suppressive effect of IL-27 on encephalitogenic Th17 cells and the effector phase of experimental autoimmune encephalomyelitis. J Immunol 2007;179:3268-3275
71. Li J, Gran B, Zhang GX, et al. IL-27 subunits and its receptor (WSX-1) mRNAs are markedly up-regulated in inflammatory cells in the CNS during experimental autoimmune encephalomyelitis. J Neurol Sci 2005;232:3-9 (Pubitemid 40585836)
72. Smits HH, van Beelen AJ, Hessle C, et al. Commensal Gram-negative bacteria prime human dendritic cells for enhanced IL-23 and IL-27 expression and enhanced Th1 development. Eur J Immunol 2004;34:1371-1380 (Pubitemid 39256016)
73. Sonobe Y, Yawata I, Kawanokuchi J, et al. Production of IL-27 and other IL-12 family cytokines by microglia and their subpopulations. Brain Res 2005;1040:202-207 (Pubitemid 40459635)
74. Stumhofer JS, Laurence A, Wilson EH, et al. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat Immunol 2006;7:937-945 (Pubitemid 44263907)
75. Stumhofer JS, Hunter CA. Advances in understanding the anti-inflammatory properties of IL-27. Immunol Lett 2008;117:123-130
76. Liu J, Guan X, Ma X. Regulation of IL-27 p28 gene expression in macrophages through MyD88- and interferon-γ-mediated pathways. J Exp Med 2007;204:141-152 (Pubitemid 46148764)
77. Wirtz S, Becker C, Fantini MC, et al. EBV-induced gene 3 transcription is induced by TLR signaling in primary dendritic cells via NF-κB activation. J Immunol 2005;174:2814-2824 (Pubitemid 40279698)
78. Molle C, Nguyen M, Flamand V, et al. IL-27 synthesis induced by TLR ligation critically depends on IFN regulatory factor 3. J Immunol 2007;178:7607-7615 (Pubitemid 46898030)
79. Pflanz S, Hibbert L, Mattson J, et al. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J Immunol 2004;172:2225-2231 (Pubitemid 38182370)
80. Artis D, Villarino A, Silverman M, et al. The IL-27 receptor (WSX-1) is an inhibitor of innate and adaptive elements of type 2 immunity. J Immunol 2004;173:5626-5634 (Pubitemid 39392150)
81. Hibbert L, Pflanz S, De Waal Malefyt R, Kastelein RA. IL-27 and IFN-α signal via Stat1 and Stat3 and induce T-Bet and IL-12Rβ2 in naive T cells. J Interferon Cytokine Res 2003;23:513-522 (Pubitemid 37130074)
82. Takeda A, Hamano S, Yamanaka A, et al. Cutting edge: role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment. J Immunol 2003;170:4886-4890 (Pubitemid 36554716)
83. Kamiya S, Owaki T, Morishima N, et al. An indispensable role for STAT1 in IL-27-induced T-bet expression but not proliferation of naive CD4+ T cells. J Immunol 2004;173:3871-3877 (Pubitemid 39280750)
84. Villarino A, Hibbert L, Lieberman L, et al. The IL-27R (WSX-1) is required to suppress T cell hyperactivity during infection. Immunity 2003;19:645-655 (Pubitemid 37490790)
85. Holscher C, Holscher A, Ruckerl D, et al. The IL-27 receptor chain WSX-1 differentially regulates antibacterial immunity and survival during experimental tuberculosis. J Immunol 2005;174:3534-3544 (Pubitemid 40354062)
86. Rosas LE, Satoskar AA, Roth KM, et al. Interleukin-27R (WSX-1/T-cell cytokine receptor) gene-deficient mice display enhanced resistance to Leishmania donovani infection but develop severe liver immunopathology. Am J Pathol 2006;168:158-169 (Pubitemid 43062569)
87. Yoshimoto T, Yoshimoto T, Yasuda K, et al. IL-27 suppresses Th2 cell development and Th2 cytokines production from polarized Th2 cells: a novel therapeutic way for Th2-mediated allergic inflammation. J Immunol 2007;179:4415-4423
88. Batten M, Li J, Yi S, et al. Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat Immunol 2006;7:929-936 (Pubitemid 44263906)
89. Amadi-Obi A, Yu CR, Liu X, et al. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med 2007;13:711-718 (Pubitemid 46889754)
90. Neufert C, Becker C, Wirtz S, et al. IL-27 controls the development of inducible regulatory T cells and Th17 cells via differential effects on STAT1. Eur J Immunol 2007;37:1809-1816 (Pubitemid 47065120)
91. Villarino AV, Stumhofer JS, Saris CJ, et al. IL-27 limits IL-2 production during Th1 differentiation. J Immunol 2006;176:237-247 (Pubitemid 43023268)
92. Owaki T, Asakawa M, Kamiya S, et al. IL-27 suppresses CD28-mediated [correction of medicated] IL-2 production through suppressor of cytokine signaling 3. J Immunol 2006;176:2773-2780 (Pubitemid 43306936)
93. Cao Y, Doodes PD, Glant TT, Finnegan A. IL-27 induces a Th1 immune response and susceptibility to experimental arthritis. J Immunol 2008;180:922-930
94. Niedbala W, Cai B, Wei X, et al. Interleukin 27 attenuates collagen-induced arthritis. Ann Rheum Dis 2008;67:1474-1479
95. Honda K, Nakamura K, Matsui N, et al. T helper 1-inducing property of IL-27/WSX-1 signaling is required for the induction of experimental colitis. Inflamm Bowel Dis 2005;11:1044-1052 (Pubitemid 41682560)
96. Villarino AV, Artis D, Bezbradica JS, et al. IL-27R deficiency delays the onset of colitis and protects from helminth-induced pathology in a model of chronic IBD. Int Immunol 2008;20:739-752 (Pubitemid 351791518)
97. Shimizu S, Sugiyama N, Masutani K, et al. Membranous glomerulonephritis development with Th2-type immune deviations in MRL/lpr mice deficient for IL-27 receptor (WSX-1). J Immunol 2005;175:7185-7192 (Pubitemid 41713412)
98. Segal BM, Shevach EM. IL-12 unmasks latent autoimmune disease in resistant mice. J Exp Med 1996;184:771-775 (Pubitemid 26324133)
99. Chang TT, Jabs C, Sobel RA, et al. Studies in B7-deficient mice reveal a critical role for B7 costimulation in both induction and effector phases of experimental autoimmune encephalomyelitis. J Exp Med 1999;190:733-740 (Pubitemid 29428655)
100. Tompkins SM, Padilla J, Dal Canto, et al. De novo central nervous system processing of myelin antigen is required for the initiation of experimental autoimmune encephalomyelitis. J Immunol 2002;168:4173-4183 (Pubitemid 34298426)
101. Ito A, Matejuk A, Hopke C, et al. Transfer of severe experimental autoimmune encephalomyelitis by IL-12- and IL-18-potentiated T cells is estrogen sensitive. J Immunol 2003;170:4802-4809 (Pubitemid 36519990)
102. Nath N, Giri S, Prasad R, et al. 5-aminoimidazole-4-carboxamide ribonucleoside: a novel immunomodulator with therapeutic efficacy in experimental autoimmune encephalomyelitis. J Immunol 2005;175:566-574 (Pubitemid 40884363)
103. Fitzgerald DC, Zhang GX, El-behi M, et al. Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nat Immunol 2007;8:1372-1379 (Pubitemid 350131174)
104. Stumhofer JS, Silver JS, Laurence A, et al. Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat Immunol 2007;8:1363-1371 (Pubitemid 350131173)
105. Awasthi A, Carrier Y, Peron JP, et al. IA dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat Immunol 2007;8:1380-1389 (Pubitemid 350131175)
106. Jankovic D, Trinchieri G. IL-10 or not IL-10: that is the question. Nat Immunol 2007;8:1281-1283 (Pubitemid 350131163)
107. - Th1 cells are the major source of host-protective regulatory IL-10 during intracellular protozoan infection. J Exp Med 2007;204:273-283
108. - Th1 cells are the source of IL-10-mediated immune suppression in chronic cutaneous leishmaniasis. J Exp Med 2007;204:285-297
109. Trinchieri G. Interleukin-10 production by effector T cells: Th1 cells show self control. J Exp Med 2007;204:239-243 (Pubitemid 46294539)
110. Wang J, Wang G, Sun B, et al. Interleukin-27 suppresses experimental autoimmune encephalomyelitis during bone marrow stromal cell treatment. J Autoimmun 2008;30:222-229 (Pubitemid 351551502)
111. Guo B, Chang EY, Cheng G. The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. J Clin Invest 2008;118:1680-1690 (Pubitemid 351632372)
112. Shinohara ML, Kim JH, Garcia VA, Cantor H. Engagement of the type I interferon receptor on dendritic cells inhibits T helper 17 cell development: role of intracellular osteopontin. Immunity 2008;29:68-78
113. Lafaille JJ, Keere FV, Hsu AL, et al. Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from the disease. J Exp Med 1997;186:307-312 (Pubitemid 27328031)
114. Kalliolias GD, Ivashkiv LB. IL-27 activates human monocytes via STAT1 and suppresses IL-10 production but the inflammatory functions of IL-27 are abrogated by TLRs and p38. J Immunol 2008;180:6325-6333
115. Muller-Newen G. The cytokine receptor gp130: faithfully promiscuous. Sci STKE 2003:PE40. Published online 23 September 2003 doi: 10.1126/stke.2003.201. pe40
116. Coulomb-l'hermine A, Larousserie F, Pflanz S, et al. Expression of interleukin-27 by human trophoblast cells. Placenta 2007;28:1133-1140
117. Devergne O, Coulomb-l'hermine A, Capel F, et al. Expression of Epstein-Barr virus-induced gene 3, an interleukin-12 p40-related molecule, throughout human pregnancy: involvement of syncytiotrophoblasts and extravillous trophoblasts. Am J Pathol 2001;159:1763-1776 (Pubitemid 33062519)
118. Oniki S, Nagai H, Horikawa T, et al. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma. Cancer Res 2006;66:6395-6404
119. Yoshimoto T, Morishima N, Mizoguchi I, et al. Antiproliferative activity of IL-27 on melanoma. J Immunol 2008;180:6527-6535
120. Chiyo M, Shimozato O, Yu L, et al. Expression of IL-27 in murine carcinoma cells produces antitumor effects and induces protective immunity in inoculated host animals. Int J Cancer 2005;115:437-442 (Pubitemid 40663748)
121. Chiyo M, Shimozato O, Iizasa T, et al. Antitumor effects produced by transduction of dendritic cells-derived heterodimeric cytokine genes in murine colon carcinoma cells. Anticancer Res 2004;24:3763-3767 (Pubitemid 40468663)
122. Hisada M, Kamiya S, Fujita K, et al. Potent antitumor activity of interleukin-27. Cancer Res 2004;64:1152-1156 (Pubitemid 38176923)
123. Salcedo R, Stauffer JK, Lincoln E, et al. IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: role for CD8+ T cells. J Immunol 2004;173:7170-7182 (Pubitemid 39628152)
124. Shimizu M, Shimamura M, Owaki T, et al. Antiangiogenic and antitumor activities of IL-27. J Immunol 2004;1 76: 7317-7324 (Pubitemid 43849032)
125. Remoli ME, Gafa V, Giacomini E, et al. IFN-β modulates the response to TLR stimulation in human DC: involvement of IFN regulatory factor-1 (IRF-1) in IL-27 gene expression. Eur J Immunol 2007;37:3499-3508
126. Wiesemann E, Deb M, Hemmer B, et al. Early identification of interferon-beta responders by ex vivo testing in patients with multiple sclerosis. Clin Immunol 2008;128:306-313